0647 GMT - Sanofi needs mergers and acquisitions to overcome several late-stage pipelines disappointments and has the means to pursue them, Berenberg analysts say in a research note. The French drugmaker has spent more than 11 billion euros on acquisitions over the past year and has the capacity to deploy about 15 billion euros, according to Berenberg. This could be stretched to about 25 billion euros if Sanofi targets companies with drugs already on the market, Berenberg says. "Sanofi's ability to offset the Dupixent loss of exclusivity has diminished in the eyes of investors with a pivot back towards the Regeneron collaboration for a solution," the analysts say. "We would like to see Sanofi execute bolt-ons in clinical stage companies specializing in immunology, rare disease, neurology and oncology." (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 07, 2026 02:47 ET (06:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.